Nevro Corp (NYSE:NVRO) Receives $65.83 Consensus PT from Brokerages

Share on StockTwits

Nevro Corp (NYSE:NVRO) has received an average recommendation of “Hold” from the thirteen analysts that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $67.17.

Several research firms have weighed in on NVRO. ValuEngine cut Nevro from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. JMP Securities upped their price target on shares of Nevro from $70.00 to $90.00 and gave the stock a “market outperform” rating in a report on Monday, August 12th. Wells Fargo & Co upped their price target on shares of Nevro from $70.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday. Leerink Swann set a $98.00 price target on shares of Nevro and gave the stock a “buy” rating in a report on Friday, August 23rd. Finally, Canaccord Genuity upped their price target on shares of Nevro from $50.00 to $59.00 and gave the stock a “hold” rating in a report on Friday, August 9th.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. DekaBank Deutsche Girozentrale bought a new position in Nevro in the 1st quarter valued at about $2,170,000. Xact Kapitalforvaltning AB purchased a new position in Nevro in the 1st quarter valued at approximately $297,000. Marshall Wace North America L.P. grew its stake in Nevro by 27.3% in the 1st quarter. Marshall Wace North America L.P. now owns 4,390 shares of the medical equipment provider’s stock valued at $276,000 after buying an additional 941 shares in the last quarter. Redmile Group LLC purchased a new position in Nevro in the 1st quarter valued at approximately $213,000. Finally, Amundi Pioneer Asset Management Inc. purchased a new position in Nevro in the 1st quarter valued at approximately $1,525,000.

NVRO opened at $80.10 on Friday. The business’s 50-day moving average price is $85.13 and its two-hundred day moving average price is $69.36. Nevro has a 1 year low of $34.75 and a 1 year high of $91.60. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of -48.85 and a beta of 0.21. The company has a debt-to-equity ratio of 0.89, a current ratio of 6.05 and a quick ratio of 4.66.

Nevro (NYSE:NVRO) last issued its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.02). The firm had revenue of $93.60 million for the quarter, compared to the consensus estimate of $88.40 million. Nevro had a negative return on equity of 41.07% and a negative net margin of 24.51%. The company’s revenue was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.35) EPS. Sell-side analysts anticipate that Nevro will post -3.87 earnings per share for the current fiscal year.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Recommended Story: What is the CBOE Russell 2000® Volatility Index?

Analyst Recommendations for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

IPL Plastics  Price Target Cut to C$11.00 by Analysts at CIBC
IPL Plastics Price Target Cut to C$11.00 by Analysts at CIBC
Canadian Apartment Properties REIT  Given a C$58.00 Price Target at Raymond James
Canadian Apartment Properties REIT Given a C$58.00 Price Target at Raymond James
OncoCyte  Receives “Buy” Rating from Chardan Capital
OncoCyte Receives “Buy” Rating from Chardan Capital
Quasarcoin Reaches One Day Trading Volume of $1,848.00
Quasarcoin Reaches One Day Trading Volume of $1,848.00
Uniform Fiscal Object  Price Tops $0.0001 on Top Exchanges
Uniform Fiscal Object Price Tops $0.0001 on Top Exchanges
Eternity Tops One Day Trading Volume of $277.00
Eternity Tops One Day Trading Volume of $277.00


 
© 2006-2019 Zolmax.